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o Role for Triple
ntiplatelet Therapy?*
avid Antoniucci, MD
lorence, Italy
ilostazol is an inhibitor of phosphodiesterase type III in
oth platelet and vascular smooth cells with the potential for
nhibition of platelet aggregation and proliferative vessel
esponse to coronary stent implantation (1,2).
See page 280
Studies have shown that adjunctive cilostazol to dual
ntiplatelet therapy in patients undergoing percutaneous
oronary intervention (PCI) may decrease late restenosis
nd enhance inhibition of adenosine diphosphate (ADP)-
nduced platelet aggregation, providing a rationale for triple
ntiplatelet therapy (3–5). The appealing hypothesis that
riple antiplatelet therapy may provide more profound
latelet aggregation inhibition and, at the same time, less
yperplastic vessel wall response to stent implantation was
xamined in this issue of the Journal by the CILON-T
Influence of CILostazol-based triple antiplatelet therapy
N ischemic complication after drug-eluting stenT im-
lantation) trial investigators in a large cohort of all-comer
atients receiving coronary drug-eluting stents (DES) who
ere randomized to dual or triple antiplatelet therapy (6).
The primary end point of the study, based on the dual
ffect of cilostazol, was a composite of acute atherothrom-
otic events and late ischemic events (death, myocardial
nfarction, stroke, and target vessel revascularization). The
econdary end point focused on platelet aggregation inhibi-
ion as assessed by VerifyNow P2Y12 assay (Accumetrics,
an Diego, California) at discharge and at 6 months.
There was no difference between groups in the rate of the
rimary end point (8.5% in the triple antiplatelet therapy
nd 9.2% in the dual antiplatelet therapy), and as expected,
arget vessel revascularization was the most frequent event
f the primary end point (6.6% and 7.2%, respectively).
hus, in patients receiving DES, cilostazol had no effect on
he risk of clinically driven target vessel revascularization
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cci has reported that he has no relationships to disclose.ue to restenosis. This study result is not consistent with the
esults of 2 trials comparing triple antiplatelet therapy with
ual antiplatelet therapy in patients at high risk of resteno-
is, such as patients with diabetes (DECLARE [Drug-
luting stenting followed by Cilostazol treatment reduces
ate REstenosis]–Diabetes trial) and patients with long
esions (DECLARE-Long trial) (4,5).
Both studies showed a decrease in angiographic late loss
n patients randomized to adjunctive cilostazol. This differ-
nce was associated with a better clinical outcome due to a
ecreased rate of repeat revascularization. With the available
ata from the CILON-T, the DECLARE-Diabetes, and
he DECLARE-Long trials, it is not possible to explain
hese contradictory results. However, considering that all 3
tudies were open-label designed, used first-generation
ES, had a short clinical follow-up, and that, at best,
ilostazol may provide a reduction in late loss with an order
f magnitude of approximately 0.10 mm, it seems unlikely a
ignificant role of this drug for the prevention of restenosis
ith the last-generation DES.
With regard to platelet aggregation inhibition, the
ILON-T study confirmed that triple antiplatelet treat-
ent is associated with an increased platelet reactivity
nhibition as compared with standard antiplatelet treatment,
ut this effect did not translate into any clinical benefit.
owever, a substantial percentage of patients randomized
o triple antiplatelet therapy had still a high residual platelet
eactivity as assessed by VerifyNow at discharge, and a poor
latelet response to clopidogrel or clopidogrel plus cilostazol
as an independent predictor of the primary end point
hazard ratio: 1.61 for every increase in tertile).
This finding is consistent with the results of previous
tudies on responsiveness in vitro to clopidogrel in patients
eceiving DES (7–10).
High residual platelet reactivity on dual antiplatelet
reatment is frequent and associated with high risk of
hrombotic events in patients receiving coronary DES. The
harmacodynamic response to clopidogrel has a high inter-
atient variability. The mechanisms leading to a decreased
ffect of clopidogrel on platelet aggregation inhibition are
ultifactorial and include high baseline value of platelet
ggregation, diabetes, high body mass index, decreased
ntestinal absorption, and hepatic activation (11–13). More-
ver, variation in platelet function in response to clopidogrel
as been associated with interference from other drugs such
s statins, proton pump inhibitors, and calcium-channel
lockers.
Decreased intestinal absorption and hepatic activation of
he drug are affected by genetic polymorphisms that are
nder intensive investigation (11–13), and it seems unlikely
hat clopidogrel resistance in patients with genetic polymor-
hism can be overcome by increasing the dose of the drug.
Most patients who exhibit high residual platelet reactivity
fter a 600-mg loading dose of clopidogrel have no or mild
mprovement of platelet aggregation inhibition with in-
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January 18, 2011:290–1 CILON-T Trialreasing the dose of the drug. In a study based on a series of
15 patients undergoing DES-supported PCI for unpro-
ected left main disease, poor responsiveness to 600-mg
lopidogrel loading was the only independent predictor of
ate cardiac mortality and definite stent thrombosis: clopi-
ogrel nonresponders had a nearly 4-fold increase in the risk
f stent thrombosis and cardiac death as compared with
lopidogrel responders (14). Patients who were nonre-
ponders to a 600-mg loading dose of clopidogrel at the first
n vitro test were prescribed 150 mg daily of the drug or
hifted to ticlopidine, and repeat measurement of platelet
eactivity after therapeutic adjustments showed some im-
rovement in platelet aggregation inhibition in only 36% of
atients (14). Similar results in terms of persistent high
esidual platelet reactivity after increasing the dose of
lopidogrel were reported by Pena et al. (15) in a series of 7
atients who suffered stent thrombosis.
Concluded small trials using a double dose of clopidogrel
r a standard dose of clopidogrel plus cilostazol have not
rovided a definite answer about the possibility of achieving
ore appropriate platelet aggregation inhibition and better
linical outcome in patients undergoing PCI (16–18).
owever, with the available data, including also the
ILON-T trial results, it is unlikely that triple antiplatelet
herapy will overcome clopidogrel resistance.
It is still unknown whether more potent antiplatelet
gents, such as prasugrel or ticagrelor, that provide a more
redictable in vitro platelet aggregation inhibition (19,20)
ill replace clopidogrel in all patients receiving DES. Again,
t is still unknown whether nonresponsiveness to clopidogrel
ill remain a marker of increased risk of DES thrombosis
nd more generally of thrombotic events also using new
ntiplatelet agents.
In the meantime, the possibility to tailor effectively the
ntiplatelet therapy under the guidance of in vitro tests
hould be considered as an attractive option.
eprint requests and correspondence: Dr. David Antoniucci,
ivision of Cardiology, Careggi Hospital, Viale Morgagni
-50139, Florence, Italy. E-mail: david.antoniucci@virgilio.it.
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